Shockwave Medical (SWAV) Tops Q1 EPS by 24c, Raises FY Guidance

Go back to Shockwave Medical (SWAV) Tops Q1 EPS by 24c, Raises FY Guidance

Shockwave Medical Reports First Quarter 2023 Financial Results

May 8, 2023 4:02 PM EDT

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

Recent Highlights

Recognized revenue of $161.1 million for the first quarter of 2023, representing an increase of 72% from the same period in 2022Announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL Catheter following clearance by the U.S. Food and Drug... More